Antiva Biosciences
Redwood City, US · Founded 2012 · Delaware corporation · 19 employees on LinkedIn · 10 known investors
Find your way into Antiva Biosciences
362 people in our graph share verified history with the Antiva Biosciences team — schools, employers, funds. One of them is your warm intro.
Travis Bryantunlockedknows Kristine Ball · together at Ey (overlapped)
×2knows the team · via Ey
×2knows the team · via UCLA
×2knows the team · via University of California, San Diego
knows the team · via Antiva Biosciences
×3knows the team · via DePauw University
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.
Founders & leadership
Antiva Biosciences was founded in 2012 by Karl Y. Hostetler.
KY
Karl Y. HostetlerinFounderKarl Y. Hostetler is an Executive Officer and Director at Antiva Biosciences. He holds board certifications in internal medicine and endocrinology & metabolism, and has expertise in medicinal chemistry, translational research, and antiviral drug discovery.
GM
Gail MaderisinChairman of the Board
KB
Kristine BallinChief Executive OfficerShe previously led Soteria Biotherapeutics as CEO and served as chief financial officer at Menlo Therapeutics, Relypsa, and KAI Pharmaceuticals, where she also held corporate strategy responsibilities. Her board service includes Oruka Therapeutics, Atreca, and Forty Seven.
EC
Elaine ChieninChief Medical Officer
SW
Sarah WalterinSVP Nonclinical Development and Global Health Strategy
RG
Raju GadirajuinChief Technical Officer2024–2025
JS
John SaywardExecutive
Board
BR
FS
Florencia SegalBoard director
BG
WH
DK
Investors · 10
Adjuvant CapitalNew York · $10M – $25M
Brace PharmaAtlanta
Canaan PartnersStamford · $500K – $20Mvia Wende Hutton · board
Lumira VenturesToronto · $1M – $10M
MPM BioImpactBoston · $1M – $15M
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Sofinnova VenturesMenlo Park · $100K – $15M
__Twitter.png)
GaingelsreportedNew York · $200K – $500K
GV (Google Ventures)reportedMountain View · $250K – $50M
Mana VenturesreportedEstero
Reported raises · per SEC filings
Form D private placements$95.7M disclosed across 7 rounds · 2014–2023
▶$38.5MraisedOct 2024 · 21 investors · BiotechnologyRule 506(b)
▶$38.5MraisedOct 2024 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Clifford SamuelDirector
- Beni RovinskiDirector
- Florencia SegalDirector
- Gail MaderisDirector
- Kristine BallExecutive Officer, Director
- Elaine ChienExecutive Officer
- Brian GoodmanDirector
- Wende HuttonDirector
- Sarah WalterExecutive Officer
- Raju GadirajuExecutive Officer
- Offering amount
- $53M
- Amount sold
- $38.5M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.6MraisedNov 2021 · 20 investors · BiotechnologyRule 506(b)
▶$15.6MraisedNov 2021 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gail MaderisExecutive Officer, Director
- Clifford SamuelDirector
- Oranee DanielsExecutive Officer
- Steven JamesDirector
- Benjamin RovinskiDirector
- Raju GadirajuExecutive Officer
- Sarah WalterExecutive Officer
- Jenny YipDirector
- Wende HuttonDirector
- Vinzenz PloererDirector
- David KabakoffDirector
- Offering amount
- $31M
- Amount sold
- $15.6M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedJul 2018 · 8 investors · BiotechnologyRule 506(b)
▶$15MraisedJul 2018 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven P. JamesDirector
- David Kabakoff, Ph.D.Director
- Raju Gadiraju, Ph.D.Executive Officer
- Michael D. CannonDirector
- Wende S. HuttonDirector
- Vinzenz PloererDirector
- Gail MaderisExecutive Officer, Director
- Oranee DanielsExecutive Officer
- Benjamin RovinskiDirector
- Ting JiaDirector
- Sarah WalterExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.7MraisedAug 2017 · 15 investors · BiotechnologyRule 506(b)
▶$14.7MraisedAug 2017 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wendee S. HuttonDirector
- Sarah WalterExecutive Officer
- Benjamin RovinskiDirector
- Raju Gadiraju, Ph.D.Executive Officer
- Steven P. JamesDirector
- David KabakoffDirector
- Vinzenz PloererDirector
- Gail MaderisExecutive Officer, Director
- Oranee DanielsExecutive Officer
- Michael D. CannonDirector
- Offering amount
- $25.9M
- Amount sold
- $14.7M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$8.9MraisedJun 2015 · 26 investors · BiotechnologyRule 506(b)
▶$8.9MraisedJun 2015 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven JamesDirector
- Wende HuttonDirector
- John SaywardExecutive Officer
- Michael CannonDirector
- David KabakoffDirector
- William RespessDirector
- Offering amount
- $16M
- Amount sold
- $8.9M
- Proceeds to insiders
- $18.3K
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$1.7MraisedDec 2014 · 19 investors · BiotechnologyRule 506(b)
▶$1.7MraisedDec 2014 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. SullivanExecutive Officer
- Michael D. CannonDirector
- Karl Y. HostetlerExecutive Officer, Director
- John W. SaywardExecutive Officer
- William L. RespessDirector
- Offering amount
- $2.5M
- Amount sold
- $1.7M
- Minimum investment
- $1
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$1.1MraisedJul 2014 · 14 investors · BiotechnologyRule 506(b)
▶$1.1MraisedJul 2014 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. SullivanExecutive Officer
- Karl Y. HostetlerExecutive Officer, Director
- Michael D. CannonDirector
- William L. RespessDirector
- Offering amount
- $1.3M
- Amount sold
- $1.1M
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Antiva Biosciences went on to found or lead other companies.
Competitors · 6
by search overlapIovance5 shared keywordsIovance develops TIL (tumor-infiltrating lymphocyte) therapy, a personalized cancer treatment that isolates immune cells from a patient's tumor, expands them in a centralized facility using proprietary manufacturing processes, and returns them for infusion back into the patient.
Artivabio5 shared keywordsArtiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings. The company's lead product, AlloNK, combines natural killer cells with B-cell targeted monoclonal antibodies to achieve deep B-cell depletion for disease remission.
Minerva Biotechnologies4 shared keywordsMinerva Biotechnologies develops cancer and stem cell therapeutics, including cancer immunotherapies aimed at solid tumors and preventing cancer metastasis. The company also works on patient-derived stem cells for regenerative medicine.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Yuva Bioscences3 shared keywordsYuva Biosciences develops and licenses Y100, a cosmetic active ingredient that enhances mitochondrial health to reduce visible signs of aging for use in skincare and haircare products.
Therivabio3 shared keywordsTheriva Biologics is a clinical-stage company developing therapeutics for cancer and related diseases, including an oncolytic adenovirus platform (VCN-01) and enzyme-based candidates for gastrointestinal and systemic conditions (SYN-004, SYN-020). It is a publicly traded biopharmaceutical company (NYSE American: TOVX) focused on areas of high unmet medical need.
Companies competing with Antiva Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Antiva Biosciences do?
- Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.
- Who founded Antiva Biosciences?
- Antiva Biosciences was founded by Karl Y. Hostetler in 2012.
- Who are Antiva Biosciences's investors?
- Antiva Biosciences's investors include Adjuvant Capital, Brace Pharma, Canaan Partners, Lumira Ventures, MPM BioImpact, OUP (Osage University Partners), Sofinnova Ventures, Gaingels and 2 more.
- How much funding has Antiva Biosciences raised?
- Antiva Biosciences has disclosed $95.7M raised across 7 rounds.
- Where is Antiva Biosciences headquartered?
- Antiva Biosciences is headquartered in Redwood City, US.